Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 10/20 | 0.40 |
| ▸ | ROCK1 | Q13464 | 7/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | MTOR | P42345 | 3/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.34 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2588507 | 0.89 | MTOR (0.38) | ROCK2ROCK1MTORPIK3CAGSK3B | |
| SCHEMBL2587333 | 0.81 | NR4A2 (0.48) | TDP1L3MBTL1MTORPIK3CALMNA | |
| SCHEMBL2593480 | 0.80 | IRAK4 (0.41) | ROCK2ROCK1GSK3BDYRK1ALRRK2 | |
| SCHEMBL2592542 | 0.79 | CDK8 (0.50) | ROCK2ROCK1MTORPIK3CALRRK2 | |
| SCHEMBL2591434 | 0.77 | TDP1 (0.42) | TDP1L3MBTL1LMNASMN1; SMN2NR3C1 | |
| SCHEMBL2592252 | 0.77 | EZH2 (0.58) | — | |
| SCHEMBL14716614 | 0.76 | LRRK2 (0.34) | ROCK2ROCK1MTORPIK3CAGSK3B | |
| SCHEMBL12180760 | 0.70 | TDP1 (0.35) | TDP1L3MBTL1LMNASMN1; SMN2NR3C1 | |
| SCHEMBL2594243 | 0.70 | KDM4E (0.46) | ROCK2GSK3BDYRK1ALRRK2KMT2A | |
| SCHEMBL2594853 | 0.69 | LRRK2 (0.42) | MTORPIK3CAGSK3BDYRK1ALRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9018382-B2 | Indazoles | GLAXOSMITHKLINE LLC (US) | 2015-04-28 | — | — | US | disclosed |
| US-9018382-B2 | Indazoles | GLAXOSMITHKLINE LLC (US) | 2015-04-28 | — | — | US | disclosed |
| US-9018382-B2 | Indazoles | GLAXOSMITHKLINE LLC (US) | 2015-04-28 | — | — | US | disclosed |
| EP-2566328-B1 | INDAZOLES | GLAXOSMITHKLINE LLC (US) | 2015-03-04 | — | — | EP | disclosed |
| EP-2566328-B1 | INDAZOLES | GLAXOSMITHKLINE LLC (US) | 2015-03-04 | — | — | EP | disclosed |
| US-20140350013-A1 | INDAZOLES | GLAXOSMITHKLINE LLC | 2014-11-27 | — | — | US | disclosed |
| US-20140350013-A1 | INDAZOLES | GLAXOSMITHKLINE LLC | 2014-11-27 | — | — | US | disclosed |
| US-20140350013-A1 | INDAZOLES | GLAXOSMITHKLINE LLC | 2014-11-27 | — | — | US | disclosed |
| US-8846935-B2 | Indazoles | GLAXOSMITHKLINE LLC (US) | 2014-09-30 | — | — | US | disclosed |
| US-8846935-B2 | Indazoles | GLAXOSMITHKLINE LLC (US) | 2014-09-30 | — | — | US | disclosed |
| US-8846935-B2 | Indazoles | GLAXOSMITHKLINE LLC (US) | 2014-09-30 | — | — | US | disclosed |
| WO-2013067300-A1 | METHOD OF TREATMENT | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2013-05-10 | — | — | WO | disclosed |
| WO-2013067300-A1 | METHOD OF TREATMENT | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2013-05-10 | — | — | WO | disclosed |
| EP-2566328-A1 | INDAZOLES | GlaxoSmithKline LLC (US) | 2013-03-13 | — | — | EP | disclosed |
| US-20130053383-A1 | INDAZOLES | GLAXOSMITHKLINE LLC | 2013-02-28 | — | — | US | disclosed |
| US-20130053383-A1 | INDAZOLES | GLAXOSMITHKLINE LLC | 2013-02-28 | — | — | US | disclosed |
| US-20130053383-A1 | INDAZOLES | GLAXOSMITHKLINE LLC | 2013-02-28 | — | — | US | disclosed |
| WO-2011140325-A1 | INDAZOLES | GLAXOSMITHKLINE LLC (US) | 2011-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053383-A1 | INDAZOLES | IDH3A, CYP3A7, IDH3B | ROCK2 1949/4885ROCK1 1881/4885TDP1 1992/4885 |
| US-20140350013-A1 | INDAZOLES | IDH3A, CYP3A7, IDH3B | ROCK2 1949/4885ROCK1 1881/4885TDP1 1992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.